Immunovant, Inc. (IMVT)
$40.58-$3.24 (-7.39%) Today
Tiago Girao - Officer
Jay S. Stout - OfficerImmunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 24 | 116,704 | $4.50M |
| Option exercise | 14 | 252,024 | |
| Derivative transaction | 1 | 86,629 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
70 Form 4 filings on record, the earliest from Oct 11, 2024, newest first. Filing history page 3 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Melanie Gloria - Officer | Grant or award | Common Stock | 109,956 | $0.00 | - | |
| Melanie Gloria - Officer | Grant or award | Stock Option (right to buy) | 137,446 | $0.00 | - | |
| Mark S. Levine - Officer | Open-market sale | Common Stock | 4,361 | $29.53 | $129K | |
| Jay S. Stout - Officer | Open-market sale | Common Stock | 2,740 | $29.53 | $81K | |
 Michael Geffner - Officer | Open-market sale | Common Stock | 3,189 | $29.53 | $94K | |
| Peter Salzmann - Officer | Open-market sale | Common Stock | 9,095 | $28.79 | $262K | |
| William L. Macias - Officer | Open-market sale | Common Stock | 2,627 | $28.79 | $76K | |
| William L. Macias - Officer | Open-market sale | Common Stock | 561 | $28.79 | $16K | |
| Mark S. Levine - Officer | Open-market sale | Common Stock | 2,860 | $28.79 | $82K | |
| Eva Renee Barnett - Officer | Open-market sale | Common Stock | 3,271 | $28.79 | $94K | |
| Eva Renee Barnett - Officer | Open-market sale | Common Stock | 5,162 | $29.56 | $153K | |
| Peter Salzmann - Officer | Open-market sale | Common Stock | 4,460 | $29.56 | $132K |
This is as far as the anonymous view goes. Create a free account for all 70 IMVT filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Immunovant, Inc. (IMVT) had 16 insider filings in the last 90 days, with the most recent on 2026-08-28. The full record for IMVT runs to 70 Form 4 filings, the earliest from 2024-10-11. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of IMVT were filed in the last 90 days.
24 insider sales of IMVT were filed in the last 90 days, totaling $4.50M.
This page tracks IMVT Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add IMVT to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
